Tumor Biology

, Volume 37, Issue 7, pp 9473–9481 | Cite as

Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia

  • Wilson Oliveira-Santos
  • Doralina Amaral Rabello
  • Antônio Roberto Lucena-Araujo
  • Fábio Morato de Oliveira
  • Eduardo Magalhaes Rego
  • Fábio Pittella Silva
  • Felipe Saldanha-Araujo
Original Article

Abstract

SET and MYND domain containing 2 (SMYD2) and the SET and MYND domain containing 3 (SMYD3) are the most studied and well-characterized members of SMYD family. It has been demonstrated that their altered expression is associated with the progression of several solid tumors. Nevertheless, whether these methyltransferases exert any impact in chronic lymphocytic leukemia (CLL) remains unknown. Here, we investigated the gene expression profile of SMYD2 and SMYD3 in 59 samples of CLL and 10 normal B cells. The obtained results were associated with white blood cells (WBC) and platelet counts, ZAP-70 protein expression, and cytogenetic analysis. We found that SMYD2 and SMYD3 are overexpressed in CLL patients and, interestingly, patients with residual expression of both genes presented a high WBC count and complex karyotype. Furthermore, a strong correlation between SMYD2 and SMYD3 gene expression was unveiled. Our data demonstrate the association of a residual expression of SMYD2 and SMYD3 with CLL progression indicators and suggests both genes are regulated by a common transcriptional control in this type of cancer. These results may provide the basis for the development of new therapeutic strategies to prevent CLL progression.

Keywords

Chronic lymphocytic leukemia Cytogenetic Complex karyotype SMYD ZAP-70 

Notes

Acknowledgments

The present study was funded by CNPq (National Council of Technological and Scientific Development), CAPES (Coordination for the Improvement of Higher Education Personnel), and FAPDF (Federal District Research Foundation).

Authors’ contribution

WOS and DAR were both responsible for conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. ARLA was both responsible for conception and design, provision of study material or patients, collection and/or assembly of data, and manuscript writing. FMO was both responsible for conception and design, provision of study material or patients, and collection and/or assembly of data. EMR was both responsible for provision of study material or patients and collection and/or assembly of data. FPS was both responsible for conception and design, provision of study material or patients, data analysis, and manuscript writing. FSA was both responsible for conception and design, provision of study material or patients, data analysis, and manuscript writing. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50. [Internet] Available from: http://dx.doi.org/10.1038/nrc2764.PubMedGoogle Scholar
  2. 2.
    Gribben JG. How I, treat CLL up front. Blood. 2010;115:187–97.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120:4684–91.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367–75.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    De Paula Careta F, Gobessi S, Panepucci RA, Bojnik E, de Morato Oliveira F, Mazza Matos D, et al. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica. 2012;97:1246–54. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3409824&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22:211–9. [Internet] Available from: http://www.sciencedirect.com/science/article/pii/S0268960X08000210.CrossRefPubMedGoogle Scholar
  7. 7.
    Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.CrossRefPubMedGoogle Scholar
  8. 8.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–34. [Internet] Available from: http://www.bloodjournal.org/content/46/2/219.abstract.PubMedGoogle Scholar
  9. 9.
    Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23:25–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control. 2012;19:18–25. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22143059.PubMedGoogle Scholar
  11. 11.
    Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma. 2013;54:2351–64. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23480493.CrossRefPubMedGoogle Scholar
  12. 12.
    Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013;98:675–85.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gunnarsson R, Mansouri L, Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. Leuk Lymphoma. 2013;54:1583–90. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23167608.CrossRefPubMedGoogle Scholar
  14. 14.
    Kudithipudi S, Jeltsch A. Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim Biophys Acta. 2014;1846:366–79. [Internet] Available from: http://www.sciencedirect.com/science/article/pii/S0304419X14000754\n http://www.ncbi.nlm.nih.gov/pubmed/25123655.PubMedGoogle Scholar
  15. 15.
    Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia. 2014;28:44–9. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24097338.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu L, Kimball S, Liu H, Holowatyj A, Yang Z-Q. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget. 2015;6:2466–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Rabello DDA, Lucena-Araujo AR, Alves-Silva JCR, da Eira VBAS, de Vasconcellos MCC, de Oliveira FM, et al. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells Mol Dis. 2014;54:97–102. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25131810.CrossRefGoogle Scholar
  18. 18.
    Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23:677–92. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3681809&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112:950–8. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/11298590.CrossRefPubMedGoogle Scholar
  20. 20.
    Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–5. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2850970&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Lim Choi Y, et al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica. 2011;96:712–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sakamoto LHT, De Andrade RV, Felipe MSS, Motoyama AB, Pittella Silva F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk Res. 2014;38:496–502. [Internet]. Available from: http://dx.doi.org/10.1016/j.leukres.2014.01.013.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Trievel RC, Beach BM, Dirk LMA, Houtz RL, Hurley JH. Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell. 2002;111:91–103.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, Selker EU, et al. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell. 2002;111:117–27. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2713760&tool=pmcentrez&rendertype=abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Veraksa A, Kennison J, McGinnis W. DEAF-1 function is essential for the early embryonic development of Drosophila. Genesis. 2002;33:67–76. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/12112874.CrossRefPubMedGoogle Scholar
  27. 27.
    Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene. 2008;27:2686–92. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17998933.CrossRefPubMedGoogle Scholar
  28. 28.
    Komatsu S, Ichikawa D, Hirajima S, Nagata H, Nishimura Y, Kawaguchi T, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015;112:357–64. [Internet] Available from: http://dx.doi.org/10.1038/bjc.2014.543.CrossRefPubMedGoogle Scholar
  29. 29.
    Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–8. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16441421.CrossRefPubMedGoogle Scholar
  30. 30.
    Hu L, Zhu YT, Qi C, Zhu Y-J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 2009;69:4067–72. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19383909.CrossRefPubMedGoogle Scholar
  31. 31.
    Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 1994;8:1640–5.Google Scholar
  32. 32.
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29, e45. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/11328886.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987;60:2712–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18216293.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.CrossRefPubMedGoogle Scholar
  36. 36.
    Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer K. Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Curr Cancer Drug Targets. 2010;10:716–27. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20578984.CrossRefPubMedGoogle Scholar
  37. 37.
    Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–51. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16179374.CrossRefPubMedGoogle Scholar
  39. 39.
    Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444:629–32. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17108971.CrossRefPubMedGoogle Scholar
  40. 40.
    Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol. 2010;188:369–81.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005;437:1043–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 2009;23:117–24.CrossRefGoogle Scholar
  43. 43.
    Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012;14:476–86. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394190/pdf/neo1406_0476.pdf.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Saddic LA, West LE, Aslanian A, Yates JR, Rubin SM, Gozani O, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010;285:37733–40. [Internet] Available from: http://www.jbc.org/content/285/48/37733.long.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25:1628–40.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mazur PK, Reynoird N, Khatri P, Jansen PWTC, Wilkinson AW, Liu S, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510:283–7. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24847881.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74. [Internet] Available from: http://dx.doi.org/10.1038/nrc3106.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IM, Wong KK, et al. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer. 2013;133:275–85.CrossRefPubMedGoogle Scholar
  49. 49.
    Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res. 2011;35:260–4. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20732714.CrossRefPubMedGoogle Scholar
  50. 50.
    Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5’ flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005;37:1104–7. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16155568.CrossRefPubMedGoogle Scholar
  51. 51.
    Coschi CH, Dick FA. Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci. 2012;69:2009–24.CrossRefPubMedGoogle Scholar
  52. 52.
    Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74. [Internet] Available from: http://www.bloodjournal.org/content/117/2/563.abstract.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tavolaro S, Colombo T, Chiaretti S, Peragine N, Fulci V, Ricciardi MR, et al. Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. Genes Chromosomes Cancer. 2015;54:222–34. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25645730.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wilson Oliveira-Santos
    • 1
  • Doralina Amaral Rabello
    • 1
  • Antônio Roberto Lucena-Araujo
    • 2
  • Fábio Morato de Oliveira
    • 2
  • Eduardo Magalhaes Rego
    • 2
  • Fábio Pittella Silva
    • 1
  • Felipe Saldanha-Araujo
    • 1
  1. 1.Laboratory of Molecular Pathology of Cancer, Faculty of Health SciencesUniversity of BrasíliaBrasíliaBrazil
  2. 2.Department of Internal Medicine, Medical School of Ribeirão PretoUniversity of São PauloRibeirão PretoBrazil

Personalised recommendations